(Q33843614)

English

Management of selected lipid abnormalities. Hypertriglyceridemia, low HDL cholesterol, lipoprotein(a), in thyroid and renal diseases, and post-transplantation

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

1 reference

Europe PubMed Central

Management of selected lipid abnormalities. Hypertriglyceridemia, low HDL cholesterol, lipoprotein(a), in thyroid and renal diseases, and post-transplantation (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

0 references

hypertriglyceridemia

1 reference

based on heuristic

inferred from title

author name string

Rader DJ

1

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Rosas S

2

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

publication date

1 January 2000

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Medical Clinics of North America

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

84

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

43-61

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Excess parathyroid hormone adversely affects lipid metabolism in chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Cholesterol levels long-term after liver transplant

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Lipid and apolipoprotein profiles of uremic dyslipoproteinemia--relation to renal function and dialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Pathogenesis of hyperlipidemia in the nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

The compositional abnormalities of lipoproteins in diabetic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Diagnosis and classification of dyslipidemia in renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Lipid abnormalities in progressive renal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Cyclosporin A has divergent effects on plasma LDL cholesterol (LDL-C) and lipoprotein(a) [Lp(a)] levels in renal transplant recipients. Evidence for renal involvement in the maintenance of LDL-C and the elevation of Lp(a) concentrations in hemodialy

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Accelerated cholesteryl ester transfer in patients with essential hypertension and the effect of ramipril treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Hypertriglyceridemia. A metabolic consequence of chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Treatment of hyperlipidemia after heart transplantation and rationale for the Heart Transplant Lipid Registry

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Lipoprotein (a) levels in end-stage renal failure and renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Hyperhomocysteinemia, hyperfibrinogenemia, and lipoprotein (a) excess in maintenance dialysis patients: a matched case-control study.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

NIH conference. Type III hyperlipoproteinemia: diagnosis, molecular defects, pathology, and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Impact of serum lipids on long-term graft and patient survival after renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Epidemiology of triglycerides: a view from Framingham

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Therapy of post-renal transplantation hyperlipidaemia: comparative study with simvastatin and fish oil

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Lipoprotein(a) levels and heart transplantation atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar?

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

N-3 fatty acids from fish oil. Effects on plasma lipoproteins and hypertriglyceridemic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Parathyroid hormone and hyperlipemia of uremia

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Lipid parameters including Lp(a) in hemodialysis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Dyslipoproteinemia in systemic lupus erythematosus. Effect of corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Effects of hypercholesterolemia of renal hemodynamics: study in patients with nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Hyperlipidemia in liver transplant recipients: prevalence and risk factors.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Familial hyper-alpha-lipoproteinemia: Studies in eighteen kindreds

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial)

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

High-density lipoprotein--the clinical implications of recent studies

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Decreased clearance of low-density lipoprotein in patients with chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Alteration of the lipid and apolipoprotein contents of lipoprotein (a) in haemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Cardiovascular disease, fibrinogen and the acute phase response: associations with lipids and blood pressure in patients with chronic renal disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Therapy of hyperlipidemia with lovastatin in kidney transplant patients on cyclosporine A immunosuppression: three-year experience

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

The effect of pravastatin on acute rejection after kidney transplantation--a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Hyperlipidemia of chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Hyperlipidemia in solid organ transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

The "best" of cholesterols, the "worst" of cholesterols: a tale of two receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Apolipoprotein(a) phenotype-associated decrease in lipoprotein(a) plasma concentrations after renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Lipoprotein(a) in renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Effect of thyroid hormone replacement on lipoprotein(a), lipids, and apolipoproteins in subjects with hypothyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

High serum cholesterol levels in persons with 'high-normal' TSH levels: should one extend the definition of subclinical hypothyroidism?

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

A potential basis for the thrombotic risks associated with lipoprotein(a).

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Normal triglyceride levels and coronary artery disease events: the Baltimore Coronary Observational Long-Term Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Intravenous Injection of Rabbit Apolipoprotein A-I Inhibits the Progression of Atherosclerosis in Cholesterol-Fed Rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Niceritrol reduces plasma lipoprotein(a) levels in patients undergoing maintenance hemodialysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Lipid abnormalities in end stage renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

The Nephrotic Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Lipoprotein(a). Clinical approach to a unique atherogenic lipoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Increased production of apolipoprotein A-I associated with elevated plasma levels of high-density lipoproteins, apolipoprotein A-I, and lipoprotein A-I in a patient with familial hyperalphalipoproteinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

The role of apolipoprotein E genetic variants in lipoprotein disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-densi

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Effect of gemfibrozil on lipoprotein abnormalities in chronic renal insufficiency: a controlled study in human chronic renal disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Apo(a) isoforms predict risk for coronary heart disease. A study in six populations

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Effect of cyclosporine on serum lipoprotein(a) levels in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Lipoprotein abnormalities in hyperlipidemic and normolipidemic men on hemodialysis with chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Lipid-lowering therapy and long-term survival in heart transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Low-density lipoprotein metabolism and its association to plasma lipoprotein(a) in the nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Plasma high density lipoproteins. Metabolism and relationship to atherogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Effect of thyroid substitution on hypercholesterolaemia in patients with subclinical hypothyroidism: a reanalysis of intervention studies

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

The triglyceride issue revisited. Findings from the Helsinki Heart Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Hyperlipidemia in childhood nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Lipid and lipoprotein (a) concentrations in renal transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Does cyclosporin increase lipoprotein(a) concentrations in renal transplant recipients?

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

Plasma triglyceride and coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970206-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0025-7125(05)70206-6

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33843614&oldid=1971938692"